Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Camille L. Bedrosian Sells 11,442 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Camille L. Bedrosian sold 11,442 shares of the firm’s stock in a transaction on Monday, September 30th. The stock was sold at an average price of $3.20, for a total value of $36,614.40. Following the completion of the transaction, the insider now owns 143,801 shares in the company, valued at approximately $460,163.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Amylyx Pharmaceuticals Price Performance

Shares of NASDAQ:AMLX opened at $3.03 on Thursday. The firm has a 50 day simple moving average of $2.37 and a 200 day simple moving average of $2.15. The company has a market cap of $206.06 million, a price-to-earnings ratio of -2.83 and a beta of -0.62. Amylyx Pharmaceuticals, Inc. has a one year low of $1.58 and a one year high of $19.95.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.35). Amylyx Pharmaceuticals had a negative net margin of 17.86% and a negative return on equity of 15.51%. The firm had revenue of ($1.02) million for the quarter, compared to analyst estimates of $18.83 million. During the same period last year, the business earned $0.31 EPS. As a group, analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.27 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. The Goldman Sachs Group raised their target price on shares of Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the company a “neutral” rating in a report on Friday, July 12th. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Amylyx Pharmaceuticals in a research note on Wednesday, July 10th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $17.60.

Institutional Trading of Amylyx Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC raised its holdings in Amylyx Pharmaceuticals by 52,575.9% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 15,276 shares of the company’s stock valued at $43,000 after buying an additional 15,247 shares during the last quarter. Algert Global LLC bought a new position in shares of Amylyx Pharmaceuticals during the second quarter valued at $47,000. CWM LLC lifted its holdings in shares of Amylyx Pharmaceuticals by 104.2% during the second quarter. CWM LLC now owns 28,643 shares of the company’s stock worth $54,000 after purchasing an additional 14,613 shares during the period. SG Americas Securities LLC grew its stake in shares of Amylyx Pharmaceuticals by 113.6% in the second quarter. SG Americas Securities LLC now owns 55,836 shares of the company’s stock worth $106,000 after purchasing an additional 29,697 shares during the last quarter. Finally, Hsbc Holdings PLC increased its holdings in Amylyx Pharmaceuticals by 57.9% in the second quarter. Hsbc Holdings PLC now owns 76,261 shares of the company’s stock valued at $150,000 after purchasing an additional 27,954 shares during the period. 95.84% of the stock is currently owned by institutional investors.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.